Literature DB >> 10083114

Low systemic exposure to tacrolimus correlates with acute rejection.

N A Undre1, J van Hooff, M Christiaans, Y Vanrenterghem, J Donck, U Heeman, M Kohnle, B Zanker, W Land, J M Morales, A Andrés, A Schäfer, P Stevenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10083114     DOI： 10.1016/s0041-1345(98)01633-9

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  33 in total

1.  Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.

Authors:  Khemjira Yaowakulpatana; Somratai Vadcharavivad; Atiporn Ingsathit; Nutthada Areepium; Surasak Kantachuvesiri; Bunyong Phakdeekitcharoen; Chonlaphat Sukasem; Supasil Sra-Ium; Vasant Sumethkul; Chagriya Kitiyakara
Journal:  Eur J Clin Pharmacol       Date:  2015-12-04       Impact factor: 2.953

2.  A limited sampling strategy for tacrolimus in renal transplant patients.

Authors:  Binu S Mathew; Denise H Fleming; Visalakshi Jeyaseelan; Sujith J Chandy; V M Annapandian; P K Subbanna; George T John
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

3.  CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.

Authors:  Shigeru Satoh; Mitsuru Saito; Takamitsu Inoue; Hideaki Kagaya; Masatomo Miura; Kazuyuki Inoue; Atsushi Komatsuda; Norihiko Tsuchiya; Toshio Suzuki; Tomonori Habuchi
Journal:  Eur J Clin Pharmacol       Date:  2009-01-06       Impact factor: 2.953

Review 4.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

5.  Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.

Authors:  Lara Aygen Øzbay; Niels Møller; Claus Juhl; Mette Bjerre; Jan Carstens; Jørgen Rungby; Kaj Anker Jørgensen
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

6.  Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium.

Authors:  Pamala A Jacobson; William S Oetting; Ann M Brearley; Robert Leduc; Weihau Guan; David Schladt; Arthur J Matas; Vishal Lamba; Bruce A Julian; Rosalyn B Mannon; Ajay Israni
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

7.  A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts.

Authors:  Frank Stifft; Franciscus Vandermeer; Cees Neef; Sander van Kuijk; Maarten H L Christiaans
Journal:  Eur J Clin Pharmacol       Date:  2020-02-04       Impact factor: 2.953

8.  Evaluation of limited sampling strategies for tacrolimus.

Authors:  Robert A M Op den Buijsch; Afke van de Plas; Leo M L Stolk; Maarten H L Christiaans; Johannes P van Hooff; Nas A Undre; Marja P van Dieijen-Visser; Otto Bekers
Journal:  Eur J Clin Pharmacol       Date:  2007-08-22       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 10.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.